Drugs & Targets FDA approves Rezlidhia for R/R AML with a susceptible IDH1 mutation December 02, 2022Vol.48 No.43
Drugs & Targets Genentech voluntarily withdraws U.S. indication of Tecentriq for types of bladder cancer December 02, 2022Vol.48 No.43
Drugs & Targets AstraZeneca to acquire Neogene Therapeutics for $320M to develop T cell receptor therapies December 02, 2022Vol.48 No.43
Drugs & Targets FDA grants accelerated approval to Elahere for platinum-resistant ovarian cancer November 18, 2022Vol.48 No.42
Drugs & Targets Lynparza receives positive CHMP opinion for metastatic, castration-resistant prostate cancer November 18, 2022Vol.48 No.42
Drugs & Targets Fox Chase, Oryzon Genomics collaborate on Iadademstat clinical trial November 18, 2022Vol.48 No.42
Drugs & Targets MD Anderson, Exscientia collaborate to develop oncology treatments using AI November 18, 2022Vol.48 No.42
